Breast cancer survivorship: radiation-related esophageal stricture and H. heilmannii gastritis treated after therapy

Patient Info: Anonymized, Female, 70+

Biomarkers: Breast tumor biomarkers not reported; initial gastric biopsies H. pylori-negative; repeat gastric biopsies showed H. heilmannii organisms

After completing breast cancer surgery and chemoradiotherapy, post-treatment dysphagia and gastritis resolved with esophageal dilation, proton pump inhibitor therapy, and bismuth-based quadruple therapy for H. heilmannii.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Courtney's Patient Story

Patient Info: Courtney, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

As of June 2025, Courtney was recovering from Stage III ER-positive, PR-positive, HER2-negative ILC treatment after double mastectomy, Taxotere/Cytoxan chemotherapy, and 25 rounds of radiation, with reconstructive surgery delayed by radiation skin injury.

Lobular Breast Cancer AllianceRead more →

Stage 2 secretory breast cancer: surgery alone with clear margins

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: ER-positive; PR-negative; HER2-negative; secretory carcinoma; low grade

At 1-month follow-up after modified radical mastectomy, she had no surgical site infection, no arm lymphedema, no scapular winging, full shoulder range of motion, and no evidence of nodal or distant disease.

PubMed CentralRead more →

Malignant Phyllodes Tumor With Breast Rupture and 10 Years Without Recurrence

Patient Info: Anonymized, Female, 50s

No tumor recurrence was seen during 10 years of follow-up after mastectomy and radiation.

PubMed CentralRead more →

Ruptured Malignant Phyllodes Tumor Treated With Emergency Mastectomy

Patient Info: Anonymized, Female, 70+

A 71-year-old woman with a rapidly growing, bleeding malignant phyllodes tumor required emergency mastectomy followed by radiation therapy.

PubMed CentralRead more →

HER2-positive breast cancer with metastatic recurrence and complete response to T-DM1

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 IHC 3+ and hormone receptor-negative in primary and metastatic breast cancer; no liver metastases seen.

Metastatic Site: major pectoralis muscle, lung, broncho-hilar lymph…

After complete radiologic response on T-DM1, treatment was stopped after 22 months because of porto-sinusoidal vascular disorder. Seven months later, she remained asymptomatic and under surveillance with no signs of recurrent disease.

PubMed CentralRead more →

Prior breast cancer with chemoport-related SVC thrombosis causing chylothorax

Patient Info: Anonymized, Female, 70+

PET-CT ruled out residual malignancy, and the right chylothorax resolved within 48 hours after SVC angioplasty/stenting with no recurrence on 3-month follow-up imaging.

PubMed CentralRead more →

HR-Positive Breast Cancer: Sara's Patient Story

Patient Info: Sara Glenn, Female, Under 40

Biomarkers: TP53 mutation / Li-Fraumeni syndrome; ER-positive; HER2-negative

As of June 2025, Sara had completed bilateral mastectomy and reconstruction for ER-positive, HER2-negative breast cancer and was on planned 10-year tamoxifen plus intensive Li-Fraumeni syndrome surveillance for herself and her daughters.

City of HopeRead more →

BRCA1 Breast Cancer: Kathy's Survivor Story

Patient Info: Kathy Baker, Female

Biomarkers: BRCA1 mutation

As of June 2025, Kathy Baker was a breast and ovarian cancer survivor using her experience with BRCA1 testing to advocate for genetic testing access and cascade testing through My Faulty Gene.

Stage IV Breast Cancer: Queen's Patient Story

Patient Info: Queen, Female, Under 40 | Stage IV

As of June 2025, Queen was living with Stage IV/metastatic breast cancer after multiple surgeries, setbacks, spread, and another tumor, while focusing on faith, self-advocacy, and living each day fully.

The Patient StoryRead more →

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-FarberRead more →

Breast cancer history: T9 osteonecrosis mimicking spinal metastasis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER status not explicitly reported; prior tamoxifen use reported

As of June 2025, the T9 lesion that had raised concern for spinal metastasis was confirmed as osteonecrosis, and eight-month follow-up showed no evidence of recurrence or new pain episodes.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Masters, Female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Chest wall/skin near surgery incision; lymph nodes

As of May 2025, Jennifer had no reported recurrence for several years after Stage IV HER2-positive metastatic breast cancer responded completely to clinical-trial treatment with T-DM1 and neratinib; she continued annual Cleveland Clinic visits and remained active with family and volunteering.

Cleveland ClinicRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 1

As of May 2025, Tanya was recovering from chest wall surgery, ALT flap repair, and a later skin graft after developing angiosarcoma in her radiated reconstructed breast years after Stage IIIA ILC treatment.

Lobular Breast Cancer AllianceRead more →

Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →

Stage II BRCA2 Invasive Ductal Carcinoma: Onjalai's Survivor Story

Patient Info: Onjalai Brown, Female, Under 40 | Stage II

Biomarkers: Patient-specific biomarker/genetic result not reported; family history suggests BRCA2 mutation

After lumpectomy, 20 rounds of chemotherapy and 36 rounds of radiation for Stage II invasive ductal carcinoma with lymph-node involvement, Onjalai had been cancer-free for 3 years as of May 2025.

City of HopeRead more →

Ductal Carcinoma In Situ Treated With Mastectomy Using Vein-Mapping Guidance

Patient Info: Anonymized, Female, 60s

A 68-year-old woman with extensive ductal carcinoma in situ underwent mastectomy using a vein-visualization technique intended to reduce vascular injury during surgery.

PubMed CentralRead more →

Extensive Ductal Carcinoma In Situ Removed With Vein-Based Surgical Mapping

Patient Info: Anonymized, Female, 40s

A 41-year-old woman with extensive ductal carcinoma in situ had the lesion mapped against superficial breast veins to guide surgical removal.

PubMed CentralRead more →

Luminal A Breast Cancer Treated With Endocrine Therapy Before Partial Mastectomy

Patient Info: Anonymized, Female, 50s

Biomarkers: luminal A

A 56-year-old woman with luminal A invasive ductal breast cancer had marked tumor shrinkage after 3 months of endocrine therapy before partial mastectomy.

PubMed CentralRead more →

Stage IA invasive lobular breast cancer with ipsilateral marginal zone lymphoma: no recurrence after surgery and radiation

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Breast cancer was ER-positive, PR-negative, HER2-negative. Separate marginal zone lymphoma showed CD20/Bcl-2 markers

As of May 2025, five-month follow-up imaging showed no recurrence of the right breast invasive lobular carcinoma and no clinical recurrence of the ipsilateral marginal zone lymphoma.

PubMed CentralRead more →

Triple-negative sebaceous carcinoma of the breast: no recurrence after multimodality treatment

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative sebaceous breast carcinoma; EMA-positive; Ki-67 50-60%; inherited breast/ovarian cancer testing negative for pathogenic variants.

As of May 2025, after surgery, adjuvant chemotherapy, and radiation, she had 5 years of follow-up with no evidence of neoplastic recurrence.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Lauren's Survivor Story

Patient Info: Lauren Yerkes, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

As of May 2025, Lauren Yerkes was a triple-negative breast cancer survivor and founder of POST SWIM, a swimwear brand created from her post-mastectomy experience.

Breast Cancer: Honey's Survivor Story

Patient Info: Honey, Female

Honey completed surgical treatment for breast cancer with clear lymph nodes and margins. She declined radiation and chemotherapy, later stopped tamoxifen, and focused on recovery from surgical menopause symptoms and returning to art. No recurrence or metastatic disease was described.

The Patient StoryRead more →

Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed CentralRead more →